Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2013

View Archived Issues

Chemokine receptor modulators reported by AstraZeneca

Neuroprotective glutathione analogues discovered at University of Minnesota

Lundbeck presents new nAChR positive allosteric modulators

Knockout model casts doubt on the role of protein kinase M zeta type in memory

AstraZeneca presents overview of pipeline with 2012 results

Kyowa Hakko Kirin reviews highlights of 2012

ALK5 and/or ALK4 inhibitors developed at SK Chemicals

Merck & Co. presents new FIXa inhibitors

Sunshine Lake Pharma develops new agents for HCV infection

Pfizer begins phase I trial of anti-IgE vaccine using Cytos' VLP technology

Stem Cell Therapeutics and Trillium Therapeutics set to merge

Ono Pharmaceutical updates progress of third quarter of fiscal 2012

Biocancell reports data from phase IIb pancreatic cancer study

Antitrypanosomal reduces experimental pulmonary hypertension and pulmonary fibrosis

AOD-9604 shows promise in rabbit model of osteoarthritis

Verastem to evaluate VS-6063 plus paclitaxel in ovarian cancer

Nektar begins phase II trial of NKTR-102 in non-small cell lung cancer

RepliCel set to meet with German competent authority for hair cell product trial

GE Healthcare highlights recently launched technologies targeting cancer

MVA-85A tuberculosis vaccine well tolerated but not significantly effective in phase IIb trial

EMA approves label extension for Abilify

Merck Serono and Opexa Therapeutics enter MS drug agreement

Agreement entered into on phase II trial of universal factor Xa inhibitor antidote PRT-4445

Xenon receives Glybera approval milestone payment

ALK-1 signaling inhibitor dalantercept begins two new phase II trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...